A Study of the Interaction Between Tumor Susceptibility Gene Glycine N-methyltransferase (GNMT) and Lung Cancer

The recruitment status of this study is unknown because the information has not been verified recently.
Verified October 2011 by China Medical University Hospital.
Recruitment status was  Not yet recruiting
Sponsor:
Information provided by (Responsible Party):
China Medical University Hospital
ClinicalTrials.gov Identifier:
NCT01452971
First received: October 13, 2011
Last updated: October 14, 2011
Last verified: October 2011
  Purpose

Environmental carcinogens such as polycyclic aromatic hydrocarbons (PAHs) were reviewed as the major risk factors for lung cancer development. In this proposal, the investigators collected fifteen kinds of major PAHs and the investigators would like to perform the following studies:

  1. Study the gene expression and subcellular localization of GNMT in the normal-tumor tissue pairs of lung cancer patients.
  2. Study the associations of the polymorphisms of GNMT in lung cancer patients and the susceptibility to lung cancer;
  3. To assess the allelic loss at GNMT and determined the LOH rate of GNMT in the normal-tumor tissue pairs of lung cancer patients.
  4. Study the associations of the copy number variation (CNV) of GNMT and the susceptibility to lung cancer;
  5. Study the interaction between GNMT and polycyclic aromatic hydrocarbons (PAHs) in lung cancer cell lines.

Condition
Lung Cancer

Study Type: Observational
Study Design: Observational Model: Case-Only
Time Perspective: Prospective
Official Title: A Study of the Interaction Between Tumor Susceptibility Gene GNMT and Lung Cancer

Resource links provided by NLM:


Further study details as provided by China Medical University Hospital:

Estimated Enrollment: 200
Study Start Date: October 2011
Detailed Description:

Multi-functional protein Glycine N-methyltransferase (GNMT, EC2.1.1.20, localized to chromosome 6p12), affects genetic stability by a) regulating the ratio of S-adenosylmethionine (SAM) to S-adenosylhomocystine (SAH) and b) binding to folate. Based on the following observations, GNMT is classified as a tumor susceptibility gene: a) diminished GNMT expression levels in both human hepatocellular carcinoma (HCC) cell lines and tissues; b) genotypic analyses of several human GNMT gene polymorphisms showed a loss of heterozygosity in 36-47% of the genetic markers in HCC tissues and also related to the susceptibility of prostate cancer; c) GNMT binds to environmental carcinogens such as benzo(a)pyrene (BaP) and aflatoxin B1 (AFB1) and protect the liver cells by inhibiting DNA-adduct formation.

Environmental carcinogens such as polycyclic aromatic hydrocarbons (PAHs) were reviewed as the major risk factors for lung cancer development. In this proposal, the investigators collected fifteen kinds of major PAHs and would like to perform the following studies:

  1. Study the gene expression and subcellular localization of GNMT in the normal-tumor tissue pairs of lung cancer patients.
  2. Study the associations of the polymorphisms of GNMT in lung cancer patients and the susceptibility to lung cancer;
  3. To assess the allelic loss at GNMT and determined the LOH rate of GNMT in the normal-tumor tissue pairs of lung cancer patients.
  4. Study the associations of the copy number variation (CNV) of GNMT and the susceptibility to lung cancer;
  5. Study the interaction between GNMT and polycyclic aromatic hydrocarbons (PAHs) in lung cancer cell lines.

So far, the investigators have analyzed the gene expression of GNMT in the normal-tumor tissue pairs of some lung cancer patients. The investigators also analyzed the interaction between the GNMT and some PAHs using lung cancer cell lines. These data are helpful to clarify the susceptibility of lung cancer patients with the gene expression in GNMT.

This study is helpful in elucidating the role of GNMT plays in the tumorigenesis of lung cancer which may have important implications in the development of strategies for the prevention, diagnosis and treatment of lung cancer and other types of cancer.

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population

primary care clinic

Criteria

Inclusion Criteria:

  • Participant is a lung cancer patient.

Exclusion Criteria:

  • Participant is under 18 years old.
  • Participant is not a lung cancer patient.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

No Contacts or Locations Provided
  More Information

No publications provided

Responsible Party: China Medical University Hospital
ClinicalTrials.gov Identifier: NCT01452971     History of Changes
Other Study ID Numbers: DMR99-IRB-196
Study First Received: October 13, 2011
Last Updated: October 14, 2011
Health Authority: Taiwan: Institutional Review Board

Keywords provided by China Medical University Hospital:
tumor susceptibility gene
glycine N-methyltransferase (GNMT)
polycyclic aromatic hydrocarbons (PAHs)
lung cancer

Additional relevant MeSH terms:
Disease Susceptibility
Lung Neoplasms
Disease Attributes
Pathologic Processes
Respiratory Tract Neoplasms
Thoracic Neoplasms
Neoplasms by Site
Neoplasms
Lung Diseases
Respiratory Tract Diseases

ClinicalTrials.gov processed this record on August 21, 2014